Arcus Biosciences (NYSE:RCUS) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Arcus Biosciences (NYSE:RCUS – Free Report) from a sell rating to a hold rating in a research note issued to investors on Sunday.

Several other research firms have also recently weighed in on RCUS. Bank of America raised their price objective on shares of Arcus Biosciences from $17.00 to $26.00 and gave the company a “neutral” rating in a research report on Friday, November 28th. Wedbush set a $35.00 price target on shares of Arcus Biosciences and gave the company an “outperform” rating in a research note on Wednesday, October 29th. The Goldman Sachs Group raised their price target on shares of Arcus Biosciences from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday, October 30th. HC Wainwright boosted their price objective on shares of Arcus Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Wednesday, October 8th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $28.89.

Check Out Our Latest Research Report on Arcus Biosciences

Arcus Biosciences Trading Up 1.5%

RCUS stock opened at $22.25 on Friday. The business has a fifty day moving average price of $20.68 and a 200 day moving average price of $13.93. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.65 and a quick ratio of 3.65. Arcus Biosciences has a fifty-two week low of $6.50 and a fifty-two week high of $26.40. The stock has a market capitalization of $2.40 billion, a price-to-earnings ratio of -6.47 and a beta of 0.75.

Arcus Biosciences (NYSE:RCUS – Get Free Report) last posted its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The company had revenue of $26.00 million for the quarter, compared to analyst estimates of $19.89 million. During the same quarter in the previous year, the firm earned ($1.00) earnings per share. The business’s revenue was down 45.8% on a year-over-year basis. Analysts expect that Arcus Biosciences will post -3.15 EPS for the current fiscal year.

Insider Buying and Selling at Arcus Biosciences

In other news, CFO Robert C. Goeltz II sold 5,000 shares of the firm’s stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $20.00, for a total value of $100,000.00. Following the transaction, the chief financial officer directly owned 92,138 shares in the company, valued at $1,842,760. This trade represents a 5.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, President Juan C. Jaen sold 82,997 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $24.71, for a total value of $2,050,855.87. Following the completion of the sale, the president owned 954,063 shares of the company’s stock, valued at $23,574,896.73. This represents a 8.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 294,193 shares of company stock worth $6,098,761. 9.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC increased its stake in Arcus Biosciences by 59.1% in the third quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock valued at $37,000 after purchasing an additional 1,021 shares in the last quarter. SBI Securities Co. Ltd. grew its holdings in shares of Arcus Biosciences by 13,547.6% in the 3rd quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock valued at $39,000 after buying an additional 2,845 shares during the period. CWM LLC grew its holdings in shares of Arcus Biosciences by 233.6% in the 2nd quarter. CWM LLC now owns 5,441 shares of the company’s stock valued at $44,000 after buying an additional 3,810 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of Arcus Biosciences by 34.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock valued at $57,000 after buying an additional 1,796 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its stake in Arcus Biosciences by 440.3% during the 2nd quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company’s stock worth $62,000 after buying an additional 6,191 shares during the period. Institutional investors own 92.89% of the company’s stock.

About Arcus Biosciences

(Get Free Report)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

See Also